Stay updated on Milademetan Safety in AML/MDS Clinical Trial
Sign up to get notified when there's something new on the Milademetan Safety in AML/MDS Clinical Trial page.

Latest updates to the Milademetan Safety in AML/MDS Clinical Trial page
- Check6 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check13 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe study page now shows a 403 error, replacing the previous detailed study content with an access-denied message. The change removes the rich study data and presents an error state instead.SummaryDifference21%

- Check56 days agoChange DetectedThe page now shows Revision: v3.6.6, replacing the previous v3.6.5. This indicates a website/software update rather than any modification to the study content.SummaryDifference0.0%

- Check70 days agoChange DetectedPublications section updated to include a Phase 1 milademetan dose-escalation study citation and a note that publications are automatically filled from PubMed. PubMed-derived entries may not all be about this study.SummaryDifference0.2%

- Check77 days agoChange DetectedThe revision label on the page updated from v3.6.4 to v3.6.5, indicating a maintenance release. No study information or page functionality appears to be affected.SummaryDifference0.0%

Stay in the know with updates to Milademetan Safety in AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Milademetan Safety in AML/MDS Clinical Trial page.